Dr. Lui Franciosi reports
US PATENT OFFICE ACKNOWLEDGES PROVISIONAL PATENT
APPLICATION FOR USE OF SPECIFIC CANNABIS STRAIN TO ENHANCE
OPIOID ANALGESIA FILED BY VERITAS' RESEARCH ARM CANNEVERT
Veritas Pharma Inc.'s research arm, Cannevert Therapeutics Ltd., filed a provisional patent application to the United States Patent and Trademark Office on Sept. 13,
2017, for use of a specific cannabis strain to enhance the actions of opioid analgesics. An acknowledgement
letter from the USPTO was received recently which provided a filing number of U.S. 62/558,021 for this
Opioids are substances that are derived from the opium poppy plant. They bind to the human body's own
opioid receptors to provide pain relief or "analgesia" for patients with acute or chronic pain. When prescribed
legally; morphine is an example opioid analgesic. Use of these drugs for a brief time is considered safe for
pain management. However, when they are overprescribed and/or frequently misused, they produce a
sense of euphoria along with relieving pain. Hence, drug dependence can occur despite using them as
prescribed over prolonged periods with the potential of fatal overdose. Opioid overdose contributed to more
than 33,000 deaths in 2015 according to U.S. Centers for Disease Control and Prevention. Heroin and
fentanyl are the most widely known opioids for their illegal, recreational use, abuse potential and fatal
overdoses. Cannabis contains substances called cannabinoids that appear to bind to human body's own
cannabinoid receptors to also produce similar effects to those of the body's opioids in mediating analgesia
and behavioural effects. However, they do not have the same drug dependence or overdose potential.
When cannabinoids and opioids are combined, they appear to augment each other's effects synergistically.
Therefore, the combination may allow for opioids to be used at lower doses with fewer side effects for the
treatment of pain and related addiction.
According to Coherent Market Insights,* the global opioids market
was approximately $17-billion (U.S.) in 2015 and is forecasted to moderately increase to near $26-billion (U.S.) in 2024.
It indicates that legal cannabis is expected to impact the opioids market growth as it gets adopted as a safe
alternative pain-relieving therapy to opioids and it is increasingly being used to address related addiction.
According to the World Drug Report 2016, approximately 17 million people suffered from opioid drug abuse.
Veritas chief executive officer, Dr. Lui Franciosi, stated, "We are pleased with Cannevert's latest submission to protect its
discovery of a cannabis strain that could potentially reduce the dose and side effects of clinically used
opioids while maintaining a good pain-relieving effect for patients." Dr. Franciosi continued: "This strain
could be also potentially useful in addressing the current fentanyl crisis throughout North America. If we're
targeting pain or opioid addiction, we want to deliver a scientifically tested, standardized product that
clinicians can rely upon."
Also of note, Veritas Pharma has granted options to purchase 1.1 million shares to consultants of the
company under the stock option plan at an exercise price of 81 cents for a period of one year from the date
of being granted.
*Global Opioids Agonist Drugs Market, By Product Type (Codeine, Fentanyl, Meperidine, Methadone,
Morphine, Hydrocodone), Therapeutic Application (Pain Management, Cough Treatment, Diarrhea
Treatment), and Geography -- Trends, Analysis and Forecast till 2024 (Market Report March 2017).
About Veritas Pharma Inc.
Veritas Pharma is an emerging discovery and IP development company, advancing the science behind medical cannabis. The company's current research-and-development efforts are to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for real science to support medical marijuana claims.
© 2020 Canjex Publishing Ltd. All rights reserved.